A new endoscopic scoring system corresponding to histological healing using linked color imaging in ulcerative colitis: the SOUL study

Abstract

Background and study aims An important therapeutic aim in ulcerative colitis (UC) is endoscopic remission. Although an endoscopic score with white light imaging (WLI) is mainly used to evaluate endoscopic findings, the usefulness of linked color imaging (LCI) has been reported. We evaluated the relationship between LCI and histopathological findings and attempted to establish a new LCI endoscopic evaluation index for UC.

Patients and methods This study was conducted at Kyorin University, Kyoto Prefectural University, and Fukuoka University Chikushi Hospital. Ninety-two patients with a Mayo endoscopic subscore (MES) ≤ 1 who underwent colonoscopy for UC in clinical remission were included. LCI index was defined as redness (R) (Grade 0–2), area of inflammation (A) (Grade 0–3), and lymphoid follicles (L) (Grade 0–3). Histological healing was defined as Geboes score < 2B.1. Endoscopic and histopathological scores were determined by central judgment.

Results In 92 patients, 85 biopsies from the sigmoid colon and 84 biopsies from the rectum (total 169 biopsies) were evaluated. There were 22, 117, and 30 cases of Grades 0, 1, and 2, respectively in LCI index-R; 113, 34, 17, and five cases of Grades 0, 1, 2, and 3, respectively, in LCI index-A; and 124, 27, 14, and four cases of Grades 0, 1, 2, and 3, respectively, in LCI index-L. Histological healing was achieved in 84.0 % of the cases (142 of 169), and there were significant associations with histological healing or non-healing in LCI index-R (P = 0.013) and A (P = 0.0014).

Conclusions A new LCI index is useful for predicting histological healing in UC patients with MES ≤ 1 and clinical remission.

Publication History

Received: 05 October 2022

Accepted after revision: 29 March 2023

Accepted Manuscript online:
03 April 2023

Article published online:
17 May 2023

• References

• 1 Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365: 1713-1725
• 2 Ungaro R, Mehandru S, Allen PB. et al. Ulcerative colitis. Lancet 2017; 389: 1756-1770
• 3 Dulai PS, Jairath V. How do we treat inflammatory bowel diseases to aim for endoscopic remission?. Clin Gastroenterol Hepatol 2020; 18: 1300-1308
• 4 Annese V, Daperno M, Rutter MD. et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013; 7: 982-1018
• 5 Baars JE, Nuij VJ, Oldenburg B. et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 2012; 18: 1634-1640
• 6 Rosenberg L, Lawlor GO, Zenlea T. et al. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2013; 19: 779-784
• 7 Colombel JF, Rutgeerts P, Reinisch W. et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201
• 8 Meucci G, Fasoli R, Saibeni S. et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis 2012; 18: 1006-1010
• 9 Froslie KF, Jahnsen J, Moum BA. et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422
• 10 Dulai PS, Levesque BG, Feagan BG. et al. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc 2015; 82: 246-255
• 11 Lemmens B, Arijs I, Van Assche G. et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis 2013; 19: 1194-1201
• 12 Zenlea T, Yee EU, Rosenberg L. et al. Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study. Am J Gastroenterol 2016; 111: 685-690
• 13 Rosenberg L, Nanda KS, Zenlea T. et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol 2013; 11: 991-996
• 14 Korelitz BI, Sultan K, Kothari M. et al. Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. World J Gastroenterol 2014; 20: 4980-4986
• 15 Bitton A, Peppercorn MA, Antonioli DA. et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20
• 16 Ozaki R, Kobayashi T, Okabayashi S. et al. Histological risk factors to predict clinical relapse in ulcerative colitis with endoscopically normal mucosa. J Crohns Colitis 2018; 12: 1288-1294
• 17 Turner D, Ricciuto A, Lewis A. et al. STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160: 1570-1583
• 18 Fukuda H, Miura Y, Hayashi Y. et al. Linked color imaging technology facilitates early detection of flat gastric cancers. Clin J Gastroenterol 2015; 8: 385-389
• 19 Uchiyama K, Takagi T, Kashiwagi S. et al. Assessment of endoscopic mucosal healing of ulcerative colitis using linked colour imaging, a novel endoscopic enhancement system. J Crohns Colitis 2017; 11: 963-969
• 20 Takagi T, Uchiyama K, Kajiwara-Kubota M. et al. The efficacy of linked color imaging for the endoscopic diagnosis of mucosal healing in quiescent ulcerative colitis. J Gastroenterol Hepatol 2021; 36: 2448-2454
• 21 Nakase H, Uchino M, Shinzaki S. et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021; 56: 489-526
• 22 Rutgeerts P, Sandborn WJ, Feagan BG. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476
• 23 Lewis JD, Chuai S, Nessel L. et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14: 1660-1666
• 24 Nakarai A, Kato J, Hiraoka S. et al. Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. World J Gastroenterol 2014; 20: 18367-18374
• 25 Rutgeerts P, Sandborn WJ, Feagan BG. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476
• 26 Jauregui-Amezaga A, Geerits A, Das Y. et al. A simplified Geboes Score for ulcerative colitis. J Crohns Colitis 2017; 11: 305-313
• 27 Mosli MH, Feagan BG, Zou G. et al. Development and validation of a histological index for UC. Gut 2017; 66: 50-58
• 28 Sands BE, Sandborn WJ, Panaccione R. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2019; 381: 1201-1214
• 29 Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measurement 1960; 20: 37-46
• 30 Bryant RV, Winer S, Travis SPL. et al. Systematic review: Histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 2014; 8: 1582-1597
• 31 Yoon H, Jangi S, Dulai PS. et al. Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis. Gastroenterology 2020; 159: 1262-1275
• 32 Hayashi R, Ueno Y, Tanaka S. et al. Rectal lymphoid follicle aphthous lesions frequently progress to ulcerative colitis with proximal extension. Intern Med 2019; 58: 625-631